SCHEMBL24256883

SCHEMBL24256883

CCCc1nc2sc(C(=O)N[C@H](C)Cc3ccc(OC)cc3)c(N)c2c2c1CCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 5/20 0.51
HPGD P15428 3/20 0.51
GAA P10253 3/20 0.51
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 1/20 0.49
ATM Q13315 2/20 0.48
GLA P06280 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CDK8 P49336 1/20 0.48
CDK19 Q9BWU1 1/20 0.48
CHRM4 P08173 5/20 0.46
FLT1 P17948 1/20 0.46
LRRK2 Q5S007 1/20 0.46
RXFP1 Q9HBX9 3/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256908 1.00 KDM4E (0.51) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256362 0.90 HPGD (0.52) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256889 0.86 MTOR (0.46) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256612 0.78 MTOR (0.60) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256709 0.77 MTOR (0.61) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL26785483 0.77 KDM4E (0.56) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256381 0.76 ALDH1A1 (0.48) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256384 0.76 ALDH1A1 (0.48) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256358 0.75 KDM4E (0.52) KDM4EALDH1A1HPGDGAAMAPT
SCHEMBL24256648 0.75 KDM4E (0.62) KDM4EALDH1A1HPGDGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 KDM4E 1927/4885ALDH1A1 1934/4885HPGD 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.